For this, we initiated in vivo screens of murine tumor cell lines with known Kras mutation status (Figure 2A and Figure S1 [10]) by transplanting them into two strains of bioluminescent NF-κB reporter mice expressing ubiquitous HIV-LTR.Luciferase (HLL mice) [24] or NF-κB.GFP.Luciferase (NGL mice) [25] transgenes. The gene discussed is KRAS; the disease is neoplasm.